1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Alimta
1.2.3 Iressa
1.2.4 Avastin
1.2.5 Tarceva
1.2.6 Zykadia
1.2.7 Tagrisso
1.2.8 Xalkori
1.2.9 Cyramza
1.2.10 Opdivo
1.2.11 Alecensa
1.3 Market by Application
1.3.1 Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2017-2028)
2.2 Non-small Cell Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Non-small Cell Lung Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Non-small Cell Lung Cancer Therapeutics Market Dynamics
2.3.1 Non-small Cell Lung Cancer Therapeutics Industry Trends
2.3.2 Non-small Cell Lung Cancer Therapeutics Market Drivers
2.3.3 Non-small Cell Lung Cancer Therapeutics Market Challenges
2.3.4 Non-small Cell Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
3.4 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2021
3.5 Non-small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2023-2028)
5 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2017-2028)
6.2 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2017-2022)
6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2017-2028)
7.2 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2017-2022)
7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Therapeutics Market Size (2017-2028)
9.2 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
11.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.1.5 GlaxoSmithKline Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
11.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.3.5 AstraZeneca Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
11.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
11.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Detail
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
11.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.7.5 Eli Lilly Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
11.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2017-2022)
11.8.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
